164 related articles for article (PubMed ID: 28783596)
21. Inhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model.
Hwang RF; Yokoi K; Bucana CD; Tsan R; Killion JJ; Evans DB; Fidler IJ
Clin Cancer Res; 2003 Dec; 9(17):6534-44. PubMed ID: 14695158
[TBL] [Abstract][Full Text] [Related]
22. Expression of c-kit and platelet-derived growth factor receptors in ovarian granulosa cell tumors.
Rocconi RP; Matthews KS; Kimball KJ; Conner MG; Baker AC; Barnes MN
Reprod Sci; 2008 Sep; 15(7):673-7. PubMed ID: 18492696
[TBL] [Abstract][Full Text] [Related]
23. Preliminary evaluation of serial (18) FDG-PET/CT to assess response to toceranib phosphate therapy in canine cancer.
Leblanc AK; Miller AN; Galyon GD; Moyers TD; Long MJ; Stuckey AC; Wall JS; Morandi F
Vet Radiol Ultrasound; 2012; 53(3):348-57. PubMed ID: 22360684
[TBL] [Abstract][Full Text] [Related]
24. Transcriptome of Two Canine Prostate Cancer Cells Treated With Toceranib Phosphate Reveals Distinct Antitumor Profiles Associated With the PDGFR Pathway.
Kobayashi PE; Lainetti PF; Leis-Filho AF; Delella FK; Carvalho M; Cury SS; Carvalho RF; Fonseca-Alves CE; Laufer-Amorim R
Front Vet Sci; 2020; 7():561212. PubMed ID: 33324695
[TBL] [Abstract][Full Text] [Related]
25. Effects of toceranib phosphate (Palladia) monotherapy on multidrug resistant lymphoma in dogs.
Yamazaki H; Miura N; Lai YC; Takahashi M; Goto-Koshino Y; Yasuyuki M; Nakaichi M; Tsujimoto H; Setoguchi A; Endo Y
J Vet Med Sci; 2017 Jul; 79(7):1225-1229. PubMed ID: 28592719
[TBL] [Abstract][Full Text] [Related]
26. Expression of the platelet-derived growth factor receptor in prostate cancer and treatment implications with tyrosine kinase inhibitors.
Hofer MD; Fecko A; Shen R; Setlur SR; Pienta KG; Tomlins SA; Chinnaiyan AM; Rubin MA
Neoplasia; 2004; 6(5):503-12. PubMed ID: 15548358
[TBL] [Abstract][Full Text] [Related]
27. Antiproliferative effects of masitinib and imatinib against canine oral fibrosarcoma in vitro.
Milovancev M; Helfand SC; Marley K; Goodall CP; Löhr CV; Bracha S
BMC Vet Res; 2016 Jun; 12():85. PubMed ID: 27259510
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of the therapeutic potential of masitinib and expression of its specific targets c-Kit, PDGFR-α, PDGFR-β, and Lyn in canine prostate cancer cell lines.
Klose K; Packeiser EM; Granados-Soler JL; Hewicker-Trautwein M; Murua Escobar H; Nolte I
Vet Comp Oncol; 2022 Sep; 20(3):641-652. PubMed ID: 35384248
[TBL] [Abstract][Full Text] [Related]
29. Overexpression of platelet-derived growth factor receptor alpha in breast cancer is associated with tumour progression.
Carvalho I; Milanezi F; Martins A; Reis RM; Schmitt F
Breast Cancer Res; 2005; 7(5):R788-95. PubMed ID: 16168125
[TBL] [Abstract][Full Text] [Related]
30. Development of an in vitro model of acquired resistance to toceranib phosphate (Palladia®) in canine mast cell tumor.
Halsey CH; Gustafson DL; Rose BJ; Wolf-Ringwall A; Burnett RC; Duval DL; Avery AC; Thamm DH
BMC Vet Res; 2014 May; 10():105. PubMed ID: 24885200
[TBL] [Abstract][Full Text] [Related]
31. Antiangiogenic and antitumor activity of a selective PDGFR tyrosine kinase inhibitor, CP-673,451.
Roberts WG; Whalen PM; Soderstrom E; Moraski G; Lyssikatos JP; Wang HF; Cooper B; Baker DA; Savage D; Dalvie D; Atherton JA; Ralston S; Szewc R; Kath JC; Lin J; Soderstrom C; Tkalcevic G; Cohen BD; Pollack V; Barth W; Hungerford W; Ung E
Cancer Res; 2005 Feb; 65(3):957-66. PubMed ID: 15705896
[TBL] [Abstract][Full Text] [Related]
32. Sunitinib: a multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies.
Papaetis GS; Syrigos KN
BioDrugs; 2009; 23(6):377-89. PubMed ID: 19894779
[TBL] [Abstract][Full Text] [Related]
33. Sunitinib: from rational design to clinical efficacy.
Chow LQ; Eckhardt SG
J Clin Oncol; 2007 Mar; 25(7):884-96. PubMed ID: 17327610
[TBL] [Abstract][Full Text] [Related]
34. Phosphorylated KIT as a predictor of outcome in canine mast cell tumours treated with toceranib phosphate or vinblastine.
Thamm DH; Weishaar KM; Charles JB; Ehrhart EJ
Vet Comp Oncol; 2020 Jun; 18(2):169-175. PubMed ID: 31365175
[TBL] [Abstract][Full Text] [Related]
35. Expression of platelet-derived growth factor receptor-α/ß, vascular endothelial growth factor receptor-2, c-Abl, and c-Kit in canine granulomatous meningoencephalitis and necrotizing encephalitis.
Song JH; Yu DH; Hwang TS; Seung BJ; Sur JH; Kim YJ; Jung DI
Vet Med Sci; 2020 Nov; 6(4):965-974. PubMed ID: 32585777
[TBL] [Abstract][Full Text] [Related]
36. Tyrosine kinase inhibitors. 6. Structure-activity relationships among N- and 3-substituted 2,2'-diselenobis(1H-indoles) for inhibition of protein tyrosine kinases and comparative in vitro and in vivo studies against selected sulfur congeners.
Showalter HD; Sercel AD; Leja BM; Wolfangel CD; Ambroso LA; Elliott WL; Fry DW; Kraker AJ; Howard CT; Lu GH; Moore CW; Nelson JM; Roberts BJ; Vincent PW; Denny WA; Thompson AM
J Med Chem; 1997 Feb; 40(4):413-26. PubMed ID: 9046331
[TBL] [Abstract][Full Text] [Related]
37. Predicting Effectiveness of Imatinib Mesylate in Tumors Expressing Platelet-Derived Growth Factors (PDGF-AA, PDGF-BB), Stem Cell Factor Ligands and Their Respective Receptors (PDGFR-α, PDGFR-β, and c-kit).
Moawad EY
J Gastrointest Cancer; 2015 Sep; 46(3):272-83. PubMed ID: 25985771
[TBL] [Abstract][Full Text] [Related]
38. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision.
London CA; Malpas PB; Wood-Follis SL; Boucher JF; Rusk AW; Rosenberg MP; Henry CJ; Mitchener KL; Klein MK; Hintermeister JG; Bergman PJ; Couto GC; Mauldin GN; Michels GM
Clin Cancer Res; 2009 Jun; 15(11):3856-65. PubMed ID: 19470739
[TBL] [Abstract][Full Text] [Related]
39. Amplification of genes encoding KIT, PDGFRalpha and VEGFR2 receptor tyrosine kinases is frequent in glioblastoma multiforme.
Joensuu H; Puputti M; Sihto H; Tynninen O; Nupponen NN
J Pathol; 2005 Oct; 207(2):224-31. PubMed ID: 16021678
[TBL] [Abstract][Full Text] [Related]
40. Immunohistochemical analysis of platelet-derived growth factor receptor-alpha, -beta, c-kit, c-abl, and arg proteins in glioblastoma: possible implications for patient selection for imatinib mesylate therapy.
Haberler C; Gelpi E; Marosi C; Rössler K; Birner P; Budka H; Hainfellner JA
J Neurooncol; 2006 Jan; 76(2):105-9. PubMed ID: 16205964
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
